Review
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2007; 13(6): 830-836
Published online Feb 14, 2007. doi: 10.3748/wjg.v13.i6.830
Table 1 Anti-HBV nucleoside/nucleotide analogues under development
PhaseDrugsCompany
Phase IIIEmtricitabine (FTC)Gilead (California, USA)
Tenofovir DFGilead (California, USA)
Telbivudine (L-dT)Idenix (Massachusetts, USA)
Clevudine (L-FMAU)Gilead/Triangle (California, USA)
Phase IIElvucitabine (β-L-Fd4C)Achillion (Connecticut, USA)
Valtorcitabine (val-L-dC)Idenix (Massachusetts, USA)
Amdoxovir (DAPD)Triangle (California, USA)
Racivir [(+/-)-FTC]Pharmasset (New Jersey, USA)
LB80380LG Life Sciences (Seoul, Korea)
Phase IAlamifovir (purine nucleoside analogue)Lilly/Mitsubishi (Indiana, USA/Osaka, Japan)
MIV 210 (FLG prodrug)Medivir/GSK (Huddinge, Sweden/Brentford, UK)
Hepavir B (PMEA prodrug)Ribapharm (California, USA)
Pre-clinicalβ-L-FddCBiochem/GSK (Sante-Foy, Canada/Brentford, UK)
6- [2- (phosphonomethoxy) alkoxy]-2, 4-diaminopyrimidinesRega Institute for Medical Research, K.U.Leuven (Leuven, Belgium)
2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1, 3, 4]-oxadiazolesNational University of Singapore (Singapore)